Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Br J Haematol
; 204(4): 1238-1242, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38073116
ABSTRACT
Data regarding the use of FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in acute lymphoblastic leukaemia (ALL) are lacking. We identified 14 patients with FLT3- or IDH1/2-mutated ALL. Three early T-cell precursor-ALL patients received FLT3 or IDH2 inhibitors. Patient 1 maintains a complete remission (CR) with enasidenib after intolerance to chemotherapy. Patient 2 maintained a CR for 27 months after treatment with enasidenib for relapsed disease. Patient 3 was treated with venetoclax and gilteritinib at the time of relapse and maintained a CR with gilteritinib for 8 months. These cases suggest that FLT3 and IDH inhibitors could represent a viable therapeutic option for ALL patients with these mutations.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Triazinas
/
Leucemia Mieloide Aguda
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Aminopiridinas
/
Compostos de Anilina
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article